DE69739415D1 - Carbonsaeuren und ihre derivate und pharmazeutische zusammensetzungen die diese enthalten - Google Patents

Carbonsaeuren und ihre derivate und pharmazeutische zusammensetzungen die diese enthalten

Info

Publication number
DE69739415D1
DE69739415D1 DE69739415T DE69739415T DE69739415D1 DE 69739415 D1 DE69739415 D1 DE 69739415D1 DE 69739415 T DE69739415 T DE 69739415T DE 69739415 T DE69739415 T DE 69739415T DE 69739415 D1 DE69739415 D1 DE 69739415D1
Authority
DE
Germany
Prior art keywords
pharmaceutical compositions
carbone
derivatives
acids
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69739415T
Other languages
German (de)
English (en)
Inventor
Jacob Bar-Tana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syndromex Ltd
Original Assignee
Syndromex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndromex Ltd filed Critical Syndromex Ltd
Application granted granted Critical
Publication of DE69739415D1 publication Critical patent/DE69739415D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/602—Dicarboxylic acid esters having at least two carbon-to-carbon double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69739415T 1997-01-07 1997-12-25 Carbonsaeuren und ihre derivate und pharmazeutische zusammensetzungen die diese enthalten Expired - Lifetime DE69739415D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11997197A IL119971A (en) 1997-01-07 1997-01-07 Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
PCT/IL1997/000427 WO1998030530A1 (en) 1997-01-07 1997-12-25 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
DE69739415D1 true DE69739415D1 (de) 2009-07-02

Family

ID=11069666

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69739415T Expired - Lifetime DE69739415D1 (de) 1997-01-07 1997-12-25 Carbonsaeuren und ihre derivate und pharmazeutische zusammensetzungen die diese enthalten

Country Status (10)

Country Link
US (3) US6284903B1 (enExample)
EP (2) EP2112134B1 (enExample)
JP (2) JP2001507713A (enExample)
KR (2) KR100806927B1 (enExample)
AT (1) ATE431816T1 (enExample)
AU (1) AU742945B2 (enExample)
CA (1) CA2277075C (enExample)
DE (1) DE69739415D1 (enExample)
IL (1) IL119971A (enExample)
WO (1) WO1998030530A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6814962B1 (en) * 1994-06-02 2004-11-09 Aventis Pharma S.A. Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
IL119971A (en) * 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
IL121165A0 (en) 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
MXPA01009893A (es) 1999-04-01 2003-07-28 Esperion Therapeutics Inc Compuestos con eter, composiciones y usos de estos.
MXPA03003021A (es) 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de eter y composiciones para el control del colesterol y usos relacionados.
AU2002211667A1 (en) 2000-10-11 2002-04-22 Esperion Therapeutics, Inc. Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US7304093B2 (en) 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
CN1962596A (zh) 2000-10-11 2007-05-16 埃斯佩里安医疗公司 用于控制胆固醇以及相关用途的酮化合物以及组合物
EP1363879A2 (en) 2000-10-11 2003-11-26 Esperion Therapeutics Inc. Sulfide and disulfide compounds and compositions for cholesterol management and related uses
PT2404890T (pt) 2003-01-23 2017-10-23 Esperion Therapeutics Inc Compostos de hidroxilo e composições para gestão do colesterol e utilizações relacionadas
JP2007525408A (ja) 2003-12-24 2007-09-06 エスペリオン セラピューティクス，インコーポレイテッド コレステロール管理および関連使用のためのケトン化合物および組成物
KR20070015114A (ko) * 2003-12-30 2007-02-01 신드로멕스 리미티드 3,3,14,14 테트라메틸 헥사데칸 1,16 이산의 투여 방법
US8410109B2 (en) 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
MX2009008099A (es) 2007-02-01 2009-12-14 Resverlogix Corp Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
IL181577A0 (en) * 2007-02-26 2007-07-04 Jacob Bar Tana Combination therapy composition and methods for the treatment of cardiovascular disorders and immune-related disorders
EP2167069B1 (en) 2007-05-23 2011-10-26 Amcol International Corporation Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
KR101629356B1 (ko) 2008-06-26 2016-06-13 리스버로직스 코퍼레이션 퀴나졸리논 유도체의 제조방법
CA2747417C (en) 2009-01-08 2017-01-03 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
KR101913109B1 (ko) 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
DK2421533T3 (en) 2009-04-22 2019-01-07 Resverlogix Corp Hitherto unknown anti-inflammatory agents
PE20121544A1 (es) 2009-09-03 2012-12-02 Pfizer Vaccines Llc Vacuna de pcsk9
US8623897B2 (en) 2010-09-20 2014-01-07 Kareus Therapeutics, Sa Methods and compositions for treatment of diabetes and dyslipidemia
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
LT2773354T (lt) 2011-11-01 2019-08-12 Resverlogix Corp. Geriamosios greitai atsipalaiduojančios pakeistų chinozolinų vaisto formos
WO2013084237A1 (en) 2011-12-08 2013-06-13 Syndromex Ltd. Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
WO2014096965A2 (en) 2012-12-21 2014-06-26 Rvx Therapeutics Inc. Novel heterocyclic compounds as bromodomain inhibitors
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
WO2016149191A1 (en) 2015-03-13 2016-09-22 Esperion Therapeutics, Inc. Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
JP6903585B2 (ja) 2015-03-13 2021-07-14 レスバーロジックス コーポレイション 補体関連疾患の治療のための組成物および治療方法
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
CN107118098B (zh) * 2016-02-25 2020-07-14 中国科学院上海药物研究所 一类脂肪酸类化合物、其制备方法及其用途
US11207285B2 (en) 2016-06-02 2021-12-28 Syndromex Ltd. Diabetes treatment regimens using alpha, alpha-substituted long-chain amphipathic carboxylates
US10512624B2 (en) 2016-11-30 2019-12-24 Syndromex Ltd. Long-chain amphipathic dicarboxylic acids for treatment of diabetes type-1
US12344578B2 (en) 2019-06-21 2025-07-01 Esperion Therapeutics, Inc. Salt forms of bempedoic acid and methods for using the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268082A (en) 1969-08-08 1972-03-22 Orsymonde Improvements in or relating to bis-(carboxy-alkylene-thio)-decanes
BE755550A (fr) * 1969-09-02 1971-02-01 Parke Davis & Co Acides alcanedioiques, leurs sels et leurs esters abaissant la teneur en triglycerides du serum sanguin
US3930024A (en) * 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
US3773946A (en) * 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
FR2288516A2 (fr) 1974-10-21 1976-05-21 Orsymonde Nouveaux bis-(carboxyalcoylene-thio)-1,10 decanes et leurs derives
IL64542A0 (en) * 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
DE3423166A1 (de) 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
US4634975A (en) * 1984-09-17 1987-01-06 Progressive Dynamics, Inc. Method and apparatus for producing electromagnetic surveillance fields
JPS61171417A (ja) * 1985-01-23 1986-08-02 Wakunaga Seiyaku Kk 抗糖尿病剤
DE3512536A1 (de) * 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3634356A1 (de) * 1986-10-08 1988-04-21 Epis Sa Arzneimittel enthaltend alpha-halogenierte dicarbonsaeuren
DE4224670A1 (de) * 1992-07-25 1994-01-27 Boehringer Mannheim Gmbh Verwendung von â,w-Dicarbonsäuren als Fibrinogensenker
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
IL119971A (en) * 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
JP2003001549A (ja) * 2001-06-26 2003-01-08 Howa Mach Ltd 光電式刃具折れ検知装置

Also Published As

Publication number Publication date
AU7994798A (en) 1998-08-03
US6800772B2 (en) 2004-10-05
KR20000069934A (ko) 2000-11-25
KR20070026888A (ko) 2007-03-08
US6284903B1 (en) 2001-09-04
US20040132818A1 (en) 2004-07-08
CA2277075A1 (en) 1998-07-16
IL119971A (en) 2003-02-12
CA2277075C (en) 2010-06-22
KR100806928B1 (ko) 2008-02-22
EP2112134B1 (en) 2013-10-30
JP2010077141A (ja) 2010-04-08
WO1998030530A1 (en) 1998-07-16
EP0988274A1 (en) 2000-03-29
JP2001507713A (ja) 2001-06-12
US20020049345A1 (en) 2002-04-25
EP0988274B1 (en) 2009-05-20
EP2112134A1 (en) 2009-10-28
EP0988274A4 (en) 2000-10-18
IL119971A0 (en) 1997-04-15
AU742945B2 (en) 2002-01-17
JP5479857B2 (ja) 2014-04-23
KR100806927B1 (ko) 2008-02-22
ATE431816T1 (de) 2009-06-15

Similar Documents

Publication Publication Date Title
DE69739415D1 (de) Carbonsaeuren und ihre derivate und pharmazeutische zusammensetzungen die diese enthalten
NO890259L (no) Fremgangsmaate for fremstilling av terapeutisk aktive etylfenoksyacetamider.
EA199800290A1 (ru) (метилсульфонил) фенил-2-(5н)-фураноны в качестве ингибиторов циклооксигеназы-2
HUP9701694A3 (en) Indolinone derivatives for the treatment of disease, use thereof, pharmaceutical compositions containing these compounds
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
LU91751I2 (fr) Asenapin et ses dérivés pharmaceutiquement acceptables (SYCREST®)
BR0009864A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças, para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e para o tratamento e/ou prevenção de diabete e/ou obesidade, e, uso de um composto
CY1107939T1 (el) Συνεργικοι φαρμακευτικοι συνδυασμοι για την προληψη ή την αγωγη του διαβητη
ATE243196T1 (de) Piperidine und pyrrolidine
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
FI945975A0 (fi) Haarautuneella aminoryhmällä substituoituja tiatsoleja, menetelmiä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
NL960024I2 (nl) Farmaceutisch preparaat omvattend 3'-deoxythymidine-2'-een (3'-deoxy-2',3'-didehydrothymidine) voor de behandeling van met retrovirus besmette patiënten.
EA200301095A1 (ru) Бифенилкарбоксамиды, снижающие уровень липидов
DE69819110D1 (de) Ein Arzneimittel zur Behandlung von Fettleibigkeit und Verbesserung des lipidmetabolismus
SE8801845L (sv) Farmakologiskt aktiva substituerade bensa mider
ATE203511T1 (de) Selektive beta3-adrenergische agonisten
EP0978278A4 (en) ANTI-DIABETIC DRUGS
DE60227421D1 (de) Rmazeutische zusammensetzung und verwendung davon
ATE267832T1 (de) Substanz gm-95, verfahren zu ihrer herstellung und ihre verwendung
ATE73807T1 (de) Neue benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel sowie zwischenprodukte.
PT889044E (pt) Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central
EP2266558A3 (en) Treatment of neuropathic pain with N-methyl-D-aspartate (NMDA) receptor antagonists
AR022044A1 (es) Derivados de 1,5-benzodiazepina
ES2123796T3 (es) Derivados de acidos fosfono-succinicos y su utilizacion como medicamentos.
TH24830A (th) การเตรียมและการใช้ประโยชน์ n - ซับสทิทิวเทค 3 -แอชาไบไชคคล ( 3.2.0.) เฮปเทน

Legal Events

Date Code Title Description
8364 No opposition during term of opposition